Bibliography
Durie, BGM, et.al. Osteonecrosis of
the Jaws in Myeloma:
Analysis of Risk Factors Including
Time Dependency of Aredeia and Zometa
Use, Steroid Use and Underlying Dental Problems.
Durie,
BGM, et. al. Osteonecrosis of the Jaws in Myeloma:
Time Dependent Correlation with Aredia and Zometa Use. Blood 104:11, 2004.
Durie,
BGM, et.al.
Magnitude of Response With Myeloma Frontline
Therapy Does Not Predict Outcome:
Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials. J Clin Oncol 10: 1857-1863, 2004.
Durie,
BGM, et.al. Myeloma Management Guidelines: A Consensus Report from the Scientific Advisors of the
International Myeloma Foundation. Hem J 4: 379-398, 2003.
Estilo,
CL. Osteonecrosis
of the Maxilla and Mandible in Patients Treated with Bisphosphonates:
A Retrospective Study. J Clin Onc 22:
8008, 2004.
Marx, RE. Letter to the editor: Pamidronate
(Aredia) and Zoledronate (Zometa) Induced Avascular
Necrosis of the Jaws: A Growing Epidemic. J Oral Maxillofac
Surg 61: 1115-1117, 2003.
Ruggiero, SL, et.al. Osteonecrosis of
the Jaws Associated With the Use of Bisphosphonates:
A Review of 63 Cases. J Oral Maxillofac Surg 62:527-534, 2004.
Schuster, Michael & Dymek Joanne. Oral Cavity Avascular Bone Necrosis – A Newly Recognized Complication
of Intravenous (IV) Bisphosphonate Therapy in Cancer
Patients. Blood 104:11, 2004.
Thakkar, Snehal, et. al.
Bisphosphonate Therapy Associated with an Increased
Incidence of Mandubular/Maxillary Osteomyelitis
in Multiple Myeloma Patients. Blood
104:11, 2004.
Zarychanski, Ryan, et. al. Osteonecrosis
of the Jaw Associated withPamidronate Therapy. Blood:
104:11, 2004.